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ABSTRACT
Liver kinase B1 (LKB1; also known as STK11) is a serine/threonine
kinase and tumour suppressor that is mutated in Peutz-Jeghers
syndrome (PJS), a premalignant syndrome associated with the
development of gastrointestinal polyps. Proglucagon-expressing
enteroendocrine cells are involved in the control of glucose
homeostasis and the regulation of appetite through the secretion of
gut hormones such as glucagon-like peptide-1 (GLP-1) and peptide
tyrosine tyrosine (PYY). To determine the role of LKB1 in these cells,
we bred mice bearing floxed alleles of Lkb1 against animals carrying
Cre recombinase under proglucagon promoter control. These mice
(GluLKB1KO) were viable and displayed near-normal growth rates
and glucose homeostasis. However, they developed large polyps at
the gastro-duodenal junction, and displayed premature mortality
(death from 120 days of age). Histological analysis of the polyps
demonstrated that they had a PJS-like appearance with an arborising
smooth-muscle core. Circulating GLP-1 levels were normal in
GluLKB1KO mice and the polyps expressed low levels of the peptide,
similar to levels in the neighbouring duodenum. Lineage tracing using
a Rosa26tdRFP transgene revealed, unexpectedly, that enterocytes
within the polyps were derived from non-proglucagon-expressing
precursors, whereas connective tissue was largely derived from
proglucagon-expressing precursors. Developmental studies in wild-
type mice suggested that a subpopulation of proglucagon-expressing
cells undergo epithelial-mesenchymal transition (EMT) to become
smooth-muscle-like cells. Thus, it is likely that polyps in the
GluLKB1KO mice developed from a unique population of smooth-
muscle-like cells derived from a proglucagon-expressing precursor.
The loss of LKB1 within this subpopulation seems to be sufficient to
drive tumorigenesis.
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INTRODUCTION
The tumour suppressor liver kinase B1 (LKB1), also known as
serine/threonine kinase 11 (STK11), was first identified as a
controller of zygote polarity in Caenorhabditis elegans (Kemphues
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et al., 1988). LKB1 phosphorylates 13 members of the AMP-
activated protein kinase (AMPK) family (Lizcano et al., 2004),
including polarity-regulating kinase partitioning defective-1 (Par-1)
and its mammalian homologue, microtubule-affinity regulating
kinase-2 (MARK2) (Marx et al., 2010). The actions of LKB1 as a
tumour suppressor thus seem to be due to its role in the control of
cell polarity, as well as of cell growth, metabolism and survival.
LKB1 is one of two key upstream regulators of classical AMPK
complexes in mammalian cells. Activation of AMPK in response to
metabolic stress restrains growth factor signalling by stimulating the
tuberous sclerosis protein complex (TSC1-TSC2) (Inoki et al.,
2003), leading to the inhibition of mammalian target of rapamycin
(mTOR), and consequently to blockage of protein and lipid
synthesis (Shackelford and Shaw, 2009).
Consistent with these signalling roles, heterozygous mutation of
the LKB1 gene in humans leads to the development of Peutz-
Jeghers syndrome (PJS), a premalignant disorder characterised by
the appearance of pigmentation around the lips, gastrointestinal
polyps and an increased risk of all cancers (Boardman et al.,
1998). Gastrointestinal polyps are the main clinical feature of PJS
and these can grow to large sizes, leading to intestinal obstruction,
intussusception, infarction and bleeding. A deeper understanding
of how LKB1 restricts tumour formation, and the identification of
the intestinal cell types most prone to transformation, are thus
needed to allow the development of novel treatments for PJS, a
disease for which there are presently no approved pharmaceutical
strategies. 
Homozygous models of LKB1 deletion are difficult to study
because constitutive Lkb1−/− mice are not viable beyond embryonic
day 10 (Jishage et al., 2002; Ylikorkala et al., 2001). In contrast,
heterozygous deletion of a single Lkb1 allele leads to the appearance
of PJS-like polyps after 5 months in mice (Bardeesy et al., 2002;
Miyoshi et al., 2002). These polyps develop primarily at the gastro-
duodenal junction and have similar characteristics to polyps found
in PJS in humans (Miyoshi et al., 2002). However, the cellular
provenance of the intestinal polyps in this model has not been
established definitively. Previous studies addressing this issue
showed that mono- or biallelic deletion of Lkb1 from smooth
muscle, using a conditional Lkb1 allele and recombination mediated
by SM-CreERT2(ki), led to smaller polyps (~0.6 mm) than those
seen in Lbk1+/− mice (1.5-10 mm), and not to large occluding polyps
or to intestinal obstruction (Katajisto et al., 2008). By contrast, no
polyps were observed after targeted gastrointestinal epithelial Lkb1
deletion using a Cyp1a1-specific inducible Cre recombinase
(Shorning et al., 2009), suggesting that epithelial cells could play a
minor role in polyp development in PJS.
Enteroendocrine cells represent a small but significant population
of cells within the gut. These cells make up less than 1% of all those
within the intestine but are essential for gut physiology and,
collectively, constitute the largest endocrine organ in the body.
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Through the expression of proglucagon and prohormone convertase
(PC)1/3, enteroendocrine L cells (and to a lesser extent K cells)
synthesise and release hormones, including glucagon-like peptide-1
(GLP-1), GLP-2 and oxyntomodulin (OXM) (Habib et al., 2012).
These hormones target receptors on pancreatic β-cells and in the
central nervous system, thus regulating growth and metabolism
(Diakogiannaki et al., 2012). Hormones released by enteroendocrine
cells, including peptide tyrosine tyrosine (PYY), GLP-1, GLP-2 and
OXM, are of considerable therapeutic interest due to their
favourable influence on appetite, energy expenditure and glucose
tolerance. GLP-1 is an incretin hormone, a hormone that stimulates
the release of insulin from the pancreas. Thus, GLP-1 receptor
agonists and inhibitors of GLP-1 hydrolysis are now front-line
therapies for type 2 diabetes (T2D) (Campbell and Drucker, 2013;
Nauck, 2011), and PYY and OXM analogues, which regulate
appetite and control energy expenditure, are both currently being
developed to treat obesity. Moreover, enhanced release of these
endogenous hormones is strongly implicated in the beneficial effects
of bariatric surgery on diabetes mellitus (Karra et al., 2010). Finally,
GLP-2 is a peptide hormone that is important in the turnover of
epithelial cells (le Roux et al., 2010).
Up to now, the role of LKB1 specifically in enteroendocrine cells
has not been examined. We (Sun et al., 2010) and others (Fu et al.,
2009; Granot et al., 2009) have previously shown that LKB1 is a
powerful restrictor of pancreatic β-cell growth and development, and
plays a role in the control of insulin secretion. We have also noted
(Leclerc et al., 2011) that both LKB1 and AMPK are involved in the
control of glucagon secretion. However, and in marked contrast to
the effect of LKB1 deletion in β-cells, deletion in α-cells exerts little
effect on α-cell proliferation or mass (G.S. and G.A.R., unpublished
observation).
To elucidate the role of LKB1 in proglucagon-expressing
enteroendocrine cells, and the possible contribution of these cells or
their progenitors in the formation of polyps in PJS, we have crossed
mice bearing floxed Lkb1 alleles with mice bearing a proglucagon-
specific Cre recombinase. This has allowed us to determine the
consequences of the loss of Lkb1 gene function in cells expressing
proglucagon, which include the enteroendocrine L cells (plus a subset
of K cells), pancreatic α-cells, and GLP-1 neurons in the brainstem
[notably the nucleus tractus solitarius (NTS)] and elsewhere in the
central nervous system (Llewellyn-Smith et al., 2013).
We show that Cre-recombinase-mediated deletion of Lkb1 from
the enteroendocrine population causes the growth of large gastro-
duodenal polyps that eventually lead to death, most likely owing to
intestinal obstruction. Lineage tracing suggests that transiently
expressing proglucagon enteroendocrine precursor cells undergo
epithelial-mesenchymal transition (EMT) to become smooth-
muscle-like cells. Loss of LKB1 within these cells leads to
dysregulated growth and tumorigenesis. The present study thus
contributes towards increased understanding of the mechanism
underlying the PJS phenotype.
RESULTS
Generation of GluLKB1KO mice
In order to generate GluLKB1KO mice deleted for both alleles of
Lkb1 in proglucagon-expressing enteroendocrine cells, in pancreatic
α-cells and in GLP-1+ neurons within the brainstem and elsewhere,
we crossed Lkb1 floxed mice with animals carrying a Cre-
recombinase transgene under the control of the proglucagon
promoter located within a bacterial artificial chromosome (BAC)
(Parker et al., 2012).
Deletion of LKB1 from proglucagon-expressing cells leads
to premature mortality
GluLKB1KO mice developed normally and appeared similar to
their heterozygous and wild-type littermates. Comparison of the
growth curves of GluLKB1KO, heterozygous (GluLKB1fl/+) and
wild-type mice revealed a trend towards lower body weights in the
GluLKB1KO group, although this difference did not reach
significance (as analysed by one-way ANOVA; Fig. 1A). Most of
the conditional null animals appeared in good health and were well
groomed. However, from around 120 days after birth, GluLKB1KO
mice became bloated in appearance (Fig. 1E) and premature
mortality was observed (Fig. 1B). Thus, 11/21 (52%) of the
GluLKB1KO mice had died unexpectedly by day 164. The
remainder (10/21) displayed symptoms of distress (bloating, weight
loss or reduced activity) and were euthanized upon veterinary advice
and subjected to post-mortem examination. By contrast, 1/16 (6.2%)
wild-type mice died by 164 days of age. Heterozygous animals
displayed an intermediate mortality, with 4/16 (25%) dying before
day 200 (Fig. 1B).
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TRANSLATIONAL IMPACT
Clinical issue
Peutz-Jeghers syndrome (PJS) is a pre-malignant syndrome that poses a
considerable burden on health owing to the formation of gastrointestinal
polyposis. This disease leads to premature mortality as a result of
increased malignancy in all organs. Although mutations of the liver kinase
B1 (LKB1) tumour suppressor gene have been characterised in PJS, the
disease process towards malignancy is poorly understood. This makes
early screening for cancer extremely difficult and currently there is no
pharmaceutical treatment available for individuals with PJS. LKB1
influences several pathways that control cell growth, including 
AMP-activated protein kinase (AMPK) and mammalian target of rapamycin
(mTOR) signalling. Understanding the role of LKB1 within different types
of gastrointestinal cells is therefore of crucial importance for understanding
the disease process and the pathways leading to malignancy. Previous
research has studied the impact of LKB1 within the smooth muscle and
the epithelium of the gastrointestinal tract. Enteroendocrine cells are
specialised cells within the gut that allow the gut to communicate with the
brain and the pancreas. Here, the authors studied the impact of deleting
LKB1 within these cells to elucidate their role in PJS.
Results
In this study, the authors used mice in which LKB1 was knocked out by
deleting the floxed Lkb1 alleles using Cre recombinase under the control
of the proglucagon promoter. Deletion of LKB1 in proglucagon-
expressing enteroendocrine cells led to the formation of large gastro-
duodenal polyps and premature mortality. These polyps had the
appearance of PJS-like polyps, with an arborising smooth-muscle core.
Proglucagon-expressing enteroendocrine cells were rare within the
polyps. However, lineage tracing revealed that the connective tissue
within the polyps was derived from proglucagon-expressing precursor
cells, whereas villus-like cells were not. Lineage tracing in wild-type mice
demonstrated that small numbers of proglucagon-expressing cells
undergo epithelial-mesenchymal transition to become smooth-muscle-
like cells within the first 10 days of life. 
Implications and future directions
These results suggest that LKB1 plays a role in the dysregulation of
proglucagon-expressing enteroendocrine precursors towards
tumorigenesis. Enteroendocrine cells are a minor cell population, making
up less than 1% of the cellular content within the gut. However, deletion
of LKB1 within these cells is sufficient to induce polyp formation,
demonstrating their crucial importance in the development of PJS. LKB1
is an important determiner of gut cell fate, and targeting LKB1 or its
downstream pathways could lead to the development of novel treatments
for individuals with PJS. This work suggests that further studies are
warranted in humans to assess the role of the enteroendocrine system
in the pathogenesis of this disease.
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GluLKB1KO mice develop large polyps at the 
gastro-duodenal junction
Pathological analysis of the gastrointestinal tract during post-mortem
revealed that 8/10 homozygous GluLKB1KO mice examined
developed gastro-duodenal polyps from around 120 days (107-164
days). These were not apparent earlier in life nor did they seem to
cause any signs of obstruction or symptoms of distress until a few
days prior to death, where weight loss was observed in some cases
(6/13 animals; Fig. 1A). As a result, tumours were usually
discovered on gross pathological analysis of the gastrointestinal tract
during post-mortem (Fig. 1E,F), and were absent from wild-type
animals (Fig. 1C,D). In each case, the polyps were large [mean
(±s.d.) length 15.8±7.6 mm; mean diameter 10.6±2.0 mm; n=5].
Polyps were either pedunculated (Fig. 1H) or sessile (Fig. 1G). The
polyps were also hyperplastic and complex in structure
(Fig. 1G,H,I). It is therefore likely that small-bowel obstruction
caused by the polyps led to the weight loss and demise of
GluLKB1KO animals. In contrast, we identified tumours in only
one GluLKB1fl/+ mouse out of 16 examined. Detailed post-mortem
analysis of elderly (471 day, n=3) GluLKB1fl/+ mice revealed that
these mice had normal gastrointestinal tracts and no evident signs of
polyp formation. In two of the GluLKB1KO mice examined,
1277
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Fig. 1. Decreased lifespan and
development of gastro-duodenal
polyps following Glu-Cre-dependent
deletion of Lkb1. (A) Body weight
changes in wild-type (n=10), GluLKB1fl/+
(n=11) and GluLKB1KO (n=13) mice.
Analysis by one-way ANOVA did not
demonstrate any significant difference
between the three groups. (B) Kaplan-
Meier survival curves for wild-type,
GluLKB1fl/+ and GluLKB1KO mice.
Vertical deflections on the graph
represent censored data where the exact
date of death was unknown owing to
euthanasia of mice with ill health.
GluLKB1KO mice (n=21; red), displayed
significantly reduced lifespan and 100% of
the cohort were deceased by day 164
(Log-rank Mantel-Cox test, P<0.001).
GluLKB1fl/+ mice (blue; n=16) displayed a
trend towards reduced longevity
compared with the wild-type mice (black;
n=16). By day 197, 93.7% of the wild-type
mice had survived compared with 64.3%
of the heterozygous mice and 0% of the
homozygous knockout mice. Median
survival for the GluLKB1KO mice was 153
days. (C) Representative wild-type mouse
with normal phenotype. (D) Abdomen of a
wild-type mouse displaying normal
gastrointestinal contents. Scale bar:
5 mm. (E) Photograph of a representative
GluLKB1KO mouse demonstrating a
bloated appearance. (F) Photograph of
the abdomen of a GluLKB1KO mouse
displaying grossly distended stomach and
duodenum due to the presence of a large
gastro-duodenal polyp. Scale bar: 5 mm.
(G) Gross macroscopy of a representative
sessile polyp. (H) Haematoxylin-eosin
(H&E)-stained section of a pedunculated
polyp, demonstrating tubulovillous
architecture with finger-like glands arising
from the stalk and a core of arborizing
smooth muscle (arrow). (I) Higher
magnification of panel H. H&E staining
with 10× magnification of the polyp. Scale
bars: (G,H) 5 mm; (I) 100 μm.
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hypersplenism was evident. This feature has been previously
described in Lkb1+/− mice following haemorrhage from enlarged
polyps (Jishage et al., 2002).
A formal histopathological analysis of the tumour and of vital
organs from a representative GluLKB1KO mouse revealed that
polyps formed at the junction of the forestomach and glandular
stomach and extended into the duodenum over the Brunner’s glands
(Fig. 1G). Areas of stromal overgrowth, consisting of complex
branching tubuloglandular components, were apparent (Fig. 1H,I).
Polyps were predominantly composed of foveolar elements rather
than specialised glands and were chiefly found in the pyloric area.
Large numbers of apoptotic/senescent/oncotic cells were also seen
in areas, creating a vacuolated appearance (not shown). The polyp
exhibited a ‘hyper-mature’ architecture with deeper glandular
components being relatively less affected. In areas of stromal
overgrowth the morphology was similar to that of the human PJS
type polyps (Beggs et al., 2010). In addition, occasional small (1- to
2-mm diameter) polypoid formations were noted in the large
intestine. There were also complex formations and dilated
lymphatics in the lamina propria component (not shown) but no
definite dysplasia within any of the lesions. This is similar to the
findings in individuals with PJS, where polyps rarely exhibit
dysplasia (Bardeesy et al., 2002). Histopathological analysis of the
brain, pancreas, liver, lungs, heart, kidneys and testes was
unremarkable.
In order to confirm deletion of LKB1 in the expected target
tissues, we performed RT-PCR analysis on mRNA extracted from
GluLKB1KO mice. This analysis revealed the predominant
expression of the shorter form, derived from the recombined gene,
in the tumours from GluLKB1KO mice (supplementary material
Fig. S1). Recombination was also detected, albeit to a lesser extent,
in the NTS within the brainstem and also the olfactory bulb (not
shown), reflecting the relative scarcity of proglucagon-expressing
cells in these regions (supplementary material Fig. S1). The shorter
PCR product was also detected as a relatively minor fragment in the
colon and, to a much larger extent, in the duodenum, thus suggesting
extensive recombination in the latter region of the intestine
(supplementary material Fig. S1). The shorter fragment was not
detected in any of the above tissues from wild-type mice (not
shown).
GluLKB1KO mice display normal fasting plasma GLP-1
levels and oral glucose tolerance
We next determined whether GLP-1 can be stored and released from
the tumours (or from L cells in the rest of the gut), and might thus
affect glucose homeostasis. However, arguing against substantially
altered incretin release, GluLKB1KO mice developed unremarkably
up to ~120 days of age, maintaining normal growth (see above,
Fig. 1A) and metabolic parameters were only mildly affected
compared with wild-type animals. GluLKB1KO mice showed no
difference in fasting glucose levels compared with controls and,
whereas intraperitoneal glucose tolerance was slightly improved in
male GluLKB1KO at 5 weeks of age, the reverse was true in female
GluLKB1KO mice versus controls (supplementary material
Fig. S2A,B,D,E). No difference in oral glucose tolerance was noted
between genotypes (supplementary material Fig. S2C,F); therefore,
incretin release is also likely to have remained unchanged. Likewise,
fasting plasma GLP-1 levels were also normal in GluLKB1KO mice
(Fig. 2A).
In support of the unchanged glucose tolerance of GluLKB1KO
mice compared with control animals, GLP-1 mRNA and protein
levels were not significantly altered in the intestines of the
GluLKB1KO mice compared with the wild-type controls
(Fig. 2C,D). However, there was significant variance in these
parameters between mice, which might have led to a type-2
statistical error. To determine whether altered levels of unprocessed
GLP-1 precursors were present in the GluLKB1KO mice compared
with controls, samples were assayed for enteroglucagon (Bryant et
al., 1983) (Fig. 2B). Arguing against this possibility, intestinal
enteroglucagon levels were not significantly altered in GluLKB1KO
mice, although again there was considerable variation between
animals. In the tumours, GLP-1 mRNA and protein levels were
extremely low and were similar to those measured in wild-type
duodenum (Fig. 2C,D).
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Fig. 2. Effects of Glu-Cre-mediated LKB1 deletion
on intestinal peptide hormone expression.
(A) Fasting plasma GLP-1 levels of wild-type,
GluLKB1fl/+ and GluLKB1KO mice.
(B) Enteroglucagon levels measured by RIA following
acetic-acid extraction of gastrointestinal tissue of
wild-type and GluLKB1KO mice. (C) Quantitation of
proglucagon (GLP-1) by qRT-PCR for wild-type,
GluLKB1fl/+ and GluLKB1KO mice. (D) GLP-1 levels
measured by RIA following acetic-acid extraction of
gastrointestinal tissue. Mice were aged between 125
and 183 days. Two-way ANOVA did not detect any
significant differences between the groups.
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Lineage tracing suggests that polyps are derived from 
cells transiently expressing proglucagon that have
undergone EMT
To further investigate the mechanisms through which deletion of
LKB1 in proglucagon-expressing cells could lead to the generation
of duodenal polyps, we performed lineage-tracing studies using
Rosa26tdRFP reporter mice. In these mice, Cre-mediated
recombination leads to the excision of a STOP codon and hence the
expression of RFP (Luche et al., 2007). The presence of RFP in the
polyps of GluLKB1KO:Rosa26tdRFP mice confirmed that a
substantial proportion of tumour cells were derived from
proglucagon-expressing cells, as expected. However, unexpectedly,
the majority of RFP-labelled cells in the polyps were located in the
connective-tissue areas surrounding the villi. These cells displayed
an elongated spindle-shaped structure more similar to smooth
muscle than enteroendocrine cells (Fig. 3A-D). It is possible that
these RFP-mesenchymal cells recruit epithelial cells of non-RFP
lineage that then populate the tissue. Occasional RFP-positive cells
were apparent in the villi and were likely to correspond to
enteroendocrine cells (e.g. see wild-type colon, Fig. 3Zii).
Furthermore, analysis of the duodenum (Fig. 3E-H) of
GluLKB1KO mice revealed a similar picture, with expression of
RFP in connective-tissue cells alongside cells within the villi/crypts
that are likely to correspond to enteroendocrine cells. The duodenum
1279
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Fig. 3. Fate of proglucagon-gene-expressing intestinal cells
explored by lineage tracing. Immunohistochemistry of frozen
sections using an anti-RFP antibody and confocal microscopy
images of polyp, duodenum and colon from wild-type (‘WT’; M-
P,Y-Zii), GluLKB1fl/+ (I-L,U-X) and GluLKB1KO (A-H,Q-T) mice.
Brightfield, RFP, DAPI (nuclei localisation) and merged RFP/
DAPI images are shown. In Zii, inset shows an enlarged image
of an RFP-stained cell located within a crypt and with predicted
enterocyte morphology.
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of GluLKB1fl/+ mice contained RFP-stained cells in the centre of the
villi, but not surrounding them; these cells are likely to correspond
to smooth-muscle cells (Fig. 4I-L). RFP-labelled cells were also
present in the duodenum and colon of wild-type mice (expressing
RFP under the Cre glucagon promoter but with wild-type Lkb1
alleles; Fig. 4M-P and 4Y-Zii). In these wild-type mice, RFP-
labelled cells were seen in populations of cells that are likely to
correspond to enteroendocrine cells, as well as in those of
mesenchymal origin. However, numbers of these mesenchymal cells
were fewer than seen in the KO mice. This is described more fully
in the following section. Wild-type mice lacking RFP displayed no
fluorescence (not shown), confirming specificity of the primary
antibody.
Characterisation of RFP-positive cells within the polyp
To further characterise the RFP-positive cells within the polyps, a
series of colocalisation experiments was performed. RFP cells
colocalised with α-smooth muscle actin (α-SMA), in keeping with
their spindle-shaped mesenchymal appearance (Fig. 4A). In contrast,
and despite the fact that these cells were of a proglucagon-
expressing lineage, the SMA cells did not colocalise with GLP-1
(Fig. 4B), which was largely absent from the polyps. In keeping
with this, and as previously discussed, peptide measurements
[radioimmunoassay (RIA)] and mRNA of proglucagon within the
tumour were low (Fig. 2C,D). Although occasional GLP-1-
containing cells were seen within the tumour, these were rare. E-
cadherin, an epithelial cell-adhesion receptor, is thought to be
essential to maintain the integrity of the epithelium. It has been
previously shown that its repression is required for cells to undergo
EMT. Within the polyps, E-cadherin was found to stain enterocytes
but did not colocalise with RFP cells (Fig. 4C).
Assessment of Glu-Cre fidelity
To assess reliability of the proglucagon promoter and to ensure that
random expression of Cre was not occurring, animals carrying Glu-
Cre, driving expression of a green fluorescent reporter protein
(GFP), were examined. As expected, most proglucagon-containing
cells exhibited green fluorescence (Fig. 5A). However, and
unexpectedly, a proportion of GFP-positive cells within the villi did
not stain for proglucagon and had a mesenchymal appearance
(Fig. 5B). To further characterise these fluorescent non-proglucagon-
expressing cells, cells were co-stained for the fibroblast marker
S100A4 (fibroblast-specific protein-1) (Fig. 5C), SMA (Fig. 5D) and
a general mesenchymal marker found in myofibroblasts, vimentin
(Fig. 5E). The GFP-positive cells did not stain for S100A4 but some
GFP-positive cells resembling lacteals stained for SMA, and others
for vimentin.
To further examine L cells, and the possibility that these can
undergo EMT, an alternative model was used. mGLU124 mice
express Venus (a yellow fluorescent protein) driven by the
proglucagon promoter (Reimann et al., 2008). These cells only
fluoresce when proglucagon is expressed. In these mice,
fluorescence was only seen in the enteroendocrine L cells and not at
all in the mesenchyme layer. Subpopulations of L cells were found
to express vimentin, a traditional mesenchymal marker and inducer
of EMT (Mendez et al., 2010) (Fig. 6A). FACS analysis of mouse
small intestines (top 10 cm) revealed that, on average, 13% of Venus
cells expressed vimentin (Fig. 6C,D). This is a small percentage of
all vimentin-expressing cells (0.39%). This finding was replicated
using human tissue samples (Fig. 6B).
To study the possibility that vimentin-expressing L cells are able
to transform into mesenchymal cells, we used an alternative GFP
reporter model using the same deleter strain, GluCreROSA26-
GCaMP3 mice (see Materials and Methods), at various stages of
development. In three P0 (newborn) mice, GFP expression was
limited to epithelial cells and colocalised with proglucagon
(Fig. 7A). Some of these GFP-proglucagon cells also expressed an
EMT marker, vimentin (Fig. 7B). By day 10 (P10) small numbers
of GFP-positive mesenchymal cells were present within a minority
of villi (Fig. 7C). The majority of these co-stained with vimentin but
not with proglucagon. By day 18 (P18), GFP cells were observed in
villi, often clustered together (Fig. 7D). These were more
differentiated, resembled lacteals, and some co-stained with SMA
but not S100A4 (Fig. 7E). Thus, small numbers of proglucagon-
expressing cells undergo EMT within the first 10 days of life.
DISCUSSION
Deletion of LKB1 from proglucagon-expressing cells leads
to the development of large gastro-duodenal polyps
The principal aim of the present study was to determine the role, if
any, of LKB1 in proglucagon-expressing cells. Using a series of
lineage-tracing approaches, we show that Cre expression is likely to
mark, in addition to L cells, a population of cells that are derived
from proglucagon-expressing precursors. Importantly, similar
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.014720
Fig. 4. Immunohistological characterisation of RFP
cells within polyps. Colocalisation experiments were
performed on 7-μm frozen sections. (A) Anti-RFP
(rabbit polyclonal) and SMA (mouse monoclonal), (B)
GLP-1 (goat polyclonal) and SMA (rabbit polyclonal),
and (C) RFP (rabbit polyclonal) and E-cadherin (mouse
monoclonal). Brightfield, DAPI, red and green
fluorescence, and the merged images are shown. RFP
cells were found to colocalise with SMA; however, the
SMA-labelled cells did not colocalise with either GLP-1
or E-cadherin. Scale bars: 50 μm.
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behaviour was observed in three independent Glu-Cre founder lines
and is unlikely, therefore, to reflect mis-expression resulting from
random insertion events.
Although little evidence was obtained of a role for LKB1 in the
development of these cells in the brain, and only a minor role, if any,
in the pancreas, we demonstrate that loss of LKB1 is critically
important in the regulation of intestinal proglucagon-expressing
enteroendocrine cells (and/or proglucagon-expressing progenitor
cells). Thus, homozygous Lkb1 deletion led to the development of
large polyps at the gastro-duodenal junction; these polyps shared
similarities with both PJS polyps in humans and with those
previously described in mice lacking a single allele of Lkb1
throughout the body (Miyoshi et al., 2002).
Important quantitative differences were observed between the
growth of polyps in GluLKB1KO mice and earlier models of Lkb1
deletion in the intestine (see Introduction and below). Interestingly,
although enteroendocrine cells represent less than 1% of the total
cellular gastrointestinal tract, Lkb1 deletion in the proglucagon-
expressing cell population led to the development of tumours
averaging in size between 1 to 3 cm in mice aged between 120 and
156 days, selectively in the duodenum. These tumours were of a
similar size to those reported in 6-month-old systemic Lkb1+/− mice
(2- to 3-cm diameter) (Rossi et al., 2002). However, they were
considerably larger than those previously described in smooth-
muscle-targeted LKB1-knockout mice (0.6 mm) after deletion of
either one or both conditional alleles (Katajisto et al., 2008).
Furthermore, deletion of LKB1 within intestinal epithelial cells has
not been described to lead to polyposis (Shorning et al., 2009).
Interestingly, in this model, deletion of LKB1 throughout the
intestinal epithelium has previously been shown to inhibit the
terminal differentiation of secretory goblet cells, leading to a more
immature, less differentiated cell phenotype, suggesting that LKB1
plays a role in EMT in these cells (Shorning et al., 2009).
Thus, polyps derived from proglucagon-expressing cells or
progenitors show a remarkably enhanced potential for growth and
survival compared with existing models. However, polyps were
rarely encountered in heterozygous GluLKB1fl/+ mice (1/16), despite
accelerated mortality of these mice compared with wild-type
animals. The latter result might seem to question the quantitative
contribution of proglucagon-expressing-cell-derived tumour cells in
human PJS, in which LKB1 loss of heterozygosity (LOH) has been
found not to be a required event for polyp formation (Katajisto et
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Fig. 5. Expression of fluorescence in adult Glu-Cre mouse
small intestine. (A) Photomicrographs demonstrating green
fluorescence in a typical epithelial cell, resembling an
enteroendocrine cell, and co-staining for proglucagon (GLP-1). The
sequence in the panel shows the green fluorescence, proglucagon
stained with a secondary Alexa-Fluor-555 and finally the merged
image with Hoechst staining of the nuclei. (B) In certain cells,
fluorescence is also demonstrated in mesenchymal cells within the
villi; these cells do not co-stain for proglucagon. (C-E) Further
characterisation of these GFP-positive but GLP-1-negative cells
demonstrates that they do not co-stain with the fibroblast-specific
marker S100A1 (C), but a proportion of cells co-stain with α-SMA
(D) and others with vimentin (E). In this final panel (E), two areas of
GFP and vimentin colocalisation are highlighted (red and green
boxes) and a typical enteroendocrine cell is highlighted (yellow
box). The asterisk in D indicates a GFP-positive cell representing a
lacteal and co-staining with α-SMA.
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al., 2008). Nonetheless, and despite the absence of evident
polyposis, GluLKB1fl/+ mice also displayed a tendency towards a
shortening of lifespan (Fig. 1B).
Loss of LKB1 in proglucagon-expressing cells does not alter
glucose tolerance
In the pancreatic β-cell, LKB1 deletion leads to enhanced insulin
secretion and improved glucose tolerance (Fu et al., 2009). Other
studies (G.S. and G.A.R., unpublished observations) have revealed
that deletion of Lkb1 selectively in the pancreatic α-cell (using a
shorter and essentially pancreatic α-cell-restricted proglucagon
promoter) (Herrera, 2000) exerts only minor effects on glucagon
release and blood glucose levels, consistent with the mild
perturbations in the intraperitoneal glucose tolerance seen here
(supplementary material Fig. S2A,D). GLP-1 was virtually
undetectable in the polyps, and plasma GLP-1 levels were similar
in knockout mice compared with controls. In accordance with this,
body weight and oral glucose tolerance were similar in knockout
mice compared with controls. Had the levels of incretins been
increased in the knockout mice, we would have expected certain
metabolic consequences, such as reduced body weight and
improved glucose tolerance (Suzuki et al., 2012). 
Given the importance of LKB1 in neuron development and
polarisation (Barnes et al., 2007; Sun et al., 2011), the absence of
any evident neuronal phenotype in the present model was
surprising. We noted that there was no apparent change in the
number or morphology of GLP-1+ neurons in the NTS
(supplementary material Fig. S3), despite recombination in this
nucleus. However, the premature mortality of the null mice is 
likely to have masked any changes, such as changes in 
bodyweight, secondary to subtle alterations in the function of 
GLP-1+ neurons, or in glucagon secretion (G.S. and G.A.R.,
unpublished). Of note, we also observed recombination within the
olfactory bulb (not shown), where more GLP-1+ neurons are
located (Trapp and Richards, 2013; Merchenthaler et al., 1999),
although whether this led to any change in olfaction has not been
investigated.
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Fig. 6. Characterisation of Venus proglucagon-expressing
enteroendocrine cells. Adult mGLU124 upper small intestine was stained
for GFP and vimentin, and a green and red secondary. (A) Some sporadic
Venus cells colocalised with vimentin. Upper SI suspensions from mGLU124
mice were stained with an antibody against vimentin and a far red secondary,
as analysed by FACS. Arrows indicate representative enteroendocrine L
cells. (C) Histogram of the far red fluorescence (vimentin) of gated Venus
cells. (D) Mean and s.e.m. of Venus cells colocalising vimentin from FACS
analysis of three animals. (B) Human intestine was stained for GLP-1 and
vimentin, and green and red secondary antibodies. Some GLP-1-positive
enteroendocrine cells colocalised with vimentin.
Fig. 7. Evidence for epithelial-to-mesenchymal transition. At P0, GLU-
Cre/ROSA26-GCaMP3 mice have GFP expression limited to epithelial cells
within the small intestine, shown by cells colocalising with GLP-1 (A). No
mesenchymal cells were observed within the mesenchymal core of villi 
(n=3 animals), although some epithelial GFP cells colocalise with the
mesenchymal marker vimentin (B). In P10 mice, GFP cells are present that
do not colocalise with proglucagon but have a mesenchymal appearance
and co-stain with the mesenchymal marker vimentin (C). Finally, in P18
mice, larger numbers of GFP-expressing mesenchymal cells are present. 
A subset of these co-stain with vimentin (D), whereas others co-stain with
SMA (E).
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Predilection for polyps at the gastro-duodenal junction
Deletion of LKB1 in cells of the proglucagon-expressing lineage led
to the generation of large polyps chiefly in the duodenum. This was
a surprising finding because numbers of proglucagon-expressing
cells in this part of the gut are not excessive. Proglucagon-
expressing cells are distributed throughout the gastrointestinal tract
with increasing numbers distally and with the highest concentration
within the colon and rectum (Eissele et al., 1992). Proglucagon-
expressing enteroendocrine-cell density is genetically determined
and region-specific (Hansen et al., 2013). We have also considered
the possibility that an increased density of cells at the gastro-
duodenal junction could occur after LKB1 deletion because of a
disruption in the polarity of these cells, leading to their hyper-
proliferation in this part of the gut. However, no evidence for this
hypothesis was obtained. The present studies in wild-type mice
using RFP as a lineage tracer (Fig. 4) provided little evidence for the
presence of large numbers of proglucagon-expressing cells in the
duodenum.
In Lkb1+/− mice, a similar predilection for the development of
polyps at the gastro-duodenal junction has previously been described
(Jishage et al., 2002). It is hypothesised that this is due to the
increased mechanical forces at this point in the gut (Biancani et al.,
1980). The development of polyps at this location in our
GluLKB1KO model might be due to a variety of factors, including
mechanical forces and the nutritional environment. It is not clear
currently whether or not cells within the gastro-duodenal junction
are more prone to undergo EMT.
Epithelial-mesenchymal transition
L cells develop from common progenitor cells at the base of the
intestinal crypt. Neurogenin 3, expressed late in differentiation,
commits the cell towards an endocrine fate (Lee et al., 2002).
Although our data do not permit a definitive assignment to be made
of the progenitor cell(s) from which polyps develop after LKB1
deletion, the rapid turnover of mature L cells (4-5 days) and inability
of these cells to divide (Petersen et al., 2014) would seem to make
these less likely candidates as the immediate precursor. On the other
hand, LKB1 deletion must occur prior to the extinction of promoter
activity, i.e. while Cre is still expressed. Because we observed
relatively little proglucagon staining within polyps, we suspect that
the daughters of immature Lkb1-null L cells that have undergone
transition then go on to become transformed, and develop tumours.
Our studies of Glu-Cre animals expressing GFP reporter proteins
demonstrate that a small proportion of proglucagon-expressing cells
express an EMT marker, vimentin, and undergo EMT by day 10. In
our GluLKB1KO model, lineage-tracing studies demonstrated that
loss of LKB1 from proglucagon-expressing precursors leads to
increased numbers of cells within the duodenum (and more
abundantly in the polyps) with mesenchymal characteristics and
localisation (Fig. 4 and supplementary material Fig. S1). It is thus
likely that LKB1 signalling is required to prevent proliferation of
this cellular compartment. Polyps seem likely to develop from this
reverted population of smooth-muscle-like cells, rather than from
mature L cells, and might conceivably be influenced by tissue
damage or inflammation.
Unanswered questions
In PJS, LKB1 deficiency has been suggested to lead to the
expansion of the progenitor cell compartment and disruption of
stem-cell division leading to mucosal prolapse. Alternatively, loss
of transforming growth factor-β (TGFβ)-mediated communication
between smooth muscle cells and the epithelium has been described
after conditional deletion of the former compartment (Katajisto et
al., 2008). PJS polyps rarely carry oncogenic RAS mutations and,
although individuals with PJS have increased susceptibility to
malignancy, the gastrointestinal polyps themselves rarely show
malignant transformation (Entius et al., 2001). Likewise, APC and
K-RAS, genes frequently mutated in adenocarcinomas, are rarely
mutated in PJS (Entius et al., 2001; Gruber et al., 1998). Future
studies will be required to determine whether these or other
mutations are involved in the development of the tumours described
here in GluLKB1KO mice.
Potential of targeting the LKB1 pathway in enteroendocrine
cells in PJS and T2D
Individuals with PJS have an increased cumulative risk of cancer
development. A recent meta-analysis reported that the prevalence of
cancer was over 90% (Giardiello et al., 2000). It is not clear how
loss of LKB1 leads to tumour development. The findings of the
present study suggest an increased vulnerability of proglucagon-
expressing precursors to proliferate following loss of LKB1. It is
possible that this unique cell population provides a reservoir of
precursors for polyp generation, thus contributing to overall tumour
burden. It should be noted that testing this possibility in humans by
using lineage-tracing approaches as adopted here in the mouse is not
feasible. To date, few studies have considered the contribution of
endocrine cells towards the PJS phenotype and the evidence
available is conflicting. This might reflect the difficulties with
immunohistological techniques used to detect these cells (Krstić et
al., 2013; Udd et al., 2010).
It has been suggested that tumour formation in PJS is associated
with the downstream effects of the loss of LKB1 and the removal of
inhibition of the mTOR pathway. Rapamycin is an mTOR inhibitor
used in immunosuppressive regimes. In Lkb1+/− mice, rapamycin has
been shown to reduce tumour burden (Robinson et al., 2009). There
is currently insufficient evidence to support the use of rapamycin as
a preventative treatment in individuals with PJS (Beggs et al., 2010).
However, the development of sophisticated and targeted mTOR
inhibitors could prove useful for the treatment of PJS. On the other
hand, the apparent plasticity of proglucagon-expressing
enteroendocrine cells (or precursors), which is reminiscent of that
of pancreatic α-cells (Thorel et al., 2010), suggests that attempts to
increase the number of these cells (for example in obesity or T2D),
through the regulation of tumour suppressors or growth factors,
should be approached with due caution.
MATERIALS AND METHODS
Mouse breeding strategy
Experiments were conducted according to UK Home Office regulations.
Mice expressing Cre recombinase (iCre) under the control of the
proglucagon promoter were developed as previously described (Parker et al.,
2012). These were crossed with mice bearing floxed Lkb1 alleles (Mouse
Models of Human Cancer Consortium; http://mouse.ncifcrf.gov/) (Sun et al.,
2011; Sun et al., 2010). The resulting GluLKB1fl/fl mice were further bred
against C57BL6 Rosa26tdRFP reporter mice (Luche et al., 2007).
GluCreROSA26-GCaMP3 mice were generated by breeding the deleter
strain with Rosa26-GCaMP3 animals (Zariwala et al., 2012). Mice
expressing Venus from a BAC transgenic under the proglucagon promoter
were as described (Reimann et al., 2008).
Mouse maintenance and diet
Mice were housed in cages with 2-5 mice per cage in a pathogen-free
facility with a 12-hour light and dark cycle. Animals had unrestricted access
to standard mouse chow diet (Research Diet, New Brunswick, NJ). All in
vivo procedures were conducted at the Imperial College Central Biomedical
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Service and were performed in accordance with the Animal Scientific
Procedures Act of 1986. Mice were assessed by weekly body weights and
also by the mouse body condition score (Ullman-Culleré and Foltz, 1999).
Animals were weighed once or twice weekly and were euthanized if they
showed signs of illness.
Oral and intraperitoneal glucose tolerance tests
Mice were fasted for 15 hours, with free access to water, before 1 g/kg body
weight glucose was administered either through oral gavage or
intraperitoneally. Blood was sampled from the tail vein at 0, 15, 30, 60, 90
and 120 minutes after glucose administration (Richards et al., 2005). Blood
glucose concentration was measured with a handheld glucometer (Accu-
Chek; Roche, Burgess Hill, UK).
Measurement of GLP-1
Mice were fasted for 15 hours. Blood was sampled from the tail vein into
ice-cold heparinised tubes (Sarstedt, Beaumont Leys, UK) containing the
dipeptidyl peptidase IV (DPP IV) inhibitor, diprotin A (Bachem, Bubendorf,
Switzerland). Plasma was separated by centrifugation of blood at 2000 g for
5 minutes and total GLP-1 levels assayed using a two-site microtitre plate-
based immunoassay with electrochemical luminescence detection (Meso
Scale Discovery kit, Gaithersburg, MD).
RNA extraction, RT-PCR and qRT-PCR
Total cellular RNA was extracted with TRIzol reagent (Invitrogen, Paisley,
UK) and phenol-chloroform using a standard protocol. RNA was treated
with DNase using a kit (Applied Biosystems, Warrington, UK). Reverse
transcription was performed using a high-capacity reverse-transcriptase kit
(Applied Biosystems, Warrington, UK). The reaction conditions were as
follows: 25°C for 10 minutes, 37°C for 2 hours and 85°C for 5 seconds.
Lkb1 deletion was assessed using two pairs of primers within exon 1 (Lkb1
forward 5′-AGGTGAAGGAGGTGCTGG-3′) and exon 8 (Lkb1 reverse 5′-
TCTGGGCTTGGTGGGATA-3′). The PCR conditions were as follows:
94°C for 5 minutes, then 30 cycles of 94°C for 30 seconds, 59°C for 1
minute, 72°C for 1 minute. A prolonged extension step was carried out at
72°C for 7 minutes. The expected product sizes were 796 bp for the floxed
allele and 228 bp after Cre recombination, owing to the loss of exons 2-6 in
the transcript (Bardeesy et al., 2002).
Expression levels of proglucagon were quantified by real-time PCR
following the SYBR Green method using 25 ng of RNA. Cyclophylin was
used as a reference gene. Primers were designed using Primer Express 3.0
software (ABI, Warrington, UK). The sequences for the primers used for
RT-PCR are listed in supplementary material Table S1. Standard curves were
constructed for each primer pair to test the efficiency of the reaction.
Reaction conditions were as follows: 95°C for 2 seconds, then cycles at
95°C for 3 seconds and 60°C for 30 seconds. The melt curve conditions
were 95°C for 15 seconds, 60°C for 1 minute, 95°C for 15 seconds and 60°C
for 15 seconds. Fold change was measured by calculating 2–ΔΔCt,
normalising for cyclophylin and to the wild-type duodenum.
Immunohistochemistry
Mice under anaesthesia {ketamine [60 mg kg−1; intramuscularly (i.m.)] and
medetomidine (250 μg kg−1, i.m.)} were given heparin (500 IU/l), flushed
with phosphate-buffered saline (PBS) to remove blood and perfused
transcardially with 60 ml of phosphate-buffered 4% paraformaldehyde
(PFA), pH 7.4. Tissues were retrieved and post-fixed overnight at 4°C in 4%
PFA, then saturated in 20% sucrose overnight. Before cutting on a cryostat,
tissues were trimmed to size, embedded in OCT, and frozen using
isopentane and liquid nitrogen.
Gut sections
Gut sections were cut at 7 μm and mounted onto Superfrost Plus glass slides.
Slides were washed in PBS and then blocked for 1 hour in PBS containing
10% animal free block (Vector Laboratories, Peterborough, UK) and 0.1%
Triton X-100. Slides were incubated with primary antibody. Antibodies
used: RFP: Living Colors® DsRed Polyclonal Antibody 632496 (Clontech,
St Germain-en-Laye, France) diluted in blocking buffer (1 in 1000
overnight); rabbit polyclonal SMA Ab5695 (Abcam, Cambridge, UK) (1 in
500), mouse monoclonal IgG2a SMA, 61001 (Progen, Heidelberg,
Germany; 1 in 100), glucagon (also stains for GLP-1) rabbit polyclonal sc-
13091 (Santa Cruz; 1 in 200), glucagon goat polyclonal sc-7782 (Santa
Cruz; 1 in 100), Ki67 rabbit polyclonal ab15580 (Abcam, Cambridge, UK;
1 in 500), E-cadherin mouse monoclonal Ab76055 (Abcam, Cambridge,
UK), GFP goat polyclonal Ab5450 (Abcam, Cambridge) and Vimentin
rabbit monoclonal Ab92547 (Abcam, Cambridge). Mouse antibodies were
used in conjunction with a mouse on mouse kit BMK-2202 (Vector,
Peterborough, UK). Following this, slides were washed 3×10 minutes in
PBS and incubated with fluorescent secondary antibody, anti-rabbit IgG
(whole molecule), F(ab)2 fragment-Cy3 (Sigma-Aldrich) for 1 hour at room
temperature. Negative controls included a PBS negative control, a rabbit
serum control and frozen sections from mice lacking RFP. Image capture
was performed on a Nipkov spinning disc confocal microscope (Hodson,
Rutter, JCI, 2013) using a 20× lens or a Zeiss LSM 510 confocal
microscope. Fluorophores were excited using 491 nm and 561 nm laser
lines. DAPI was visualised at 359 nm. Emitted light was captured using
filters centred on 480/40 nm, 535/30 nm and 630/75 nm for DAPI, Alexa-
Fluor-488 and Alexa-Fluor-568, respectively. Uniform linear adjustments
were performed to contrast/brightness to improve image quality as required.
Brain sections
Coronal sections were cut at 30 μm using a cryostat and washed in 0.1 M
phosphate buffer (PB; pH 7.4). After incubation in blocking buffer
containing 10% sheep serum, 0.1% Triton X-100 diluted in 0.1 M PB for
30 minutes at room temperature, sections were transferred to 1:1000 anti-
DsRed (Clontech #632496) in blocking buffer and incubated overnight on
a shaker at 4°C. Following primary antibody incubation, sections were
washed 3×10 minutes in PB followed by incubation in 1:500 Cy3-
conjugated anti-rabbit secondary antibody (Sigma #C2306) in blocking
buffer for 2 hours on a shaker at room temperature. Sections were washed
in PB, mounted onto slides and left to air dry before being coverslipped and
viewed using epifluorescence (Nikon Eclipse 80; Kingston upon Thames,
Surrey, United Kingdom). Photomicrographs were taken with a
Micropublisher 3.3 RTV camera and QCapture Pro software (Qimaging Inc.,
Surrey, BC, Canada).
Measurement of GLP-1 and enteroglucagon from tissues
GLP-1 and enteroglucagon peptide hormones were extracted by boiling the
tissues for 15 minutes in 0.5 M acetic acid (Bryant et al., 1983). The
resulting supernatant was assayed by radioimmunoassay using in-house RIA
for enteroglucagon and GLP-1 (Bryant et al., 1983; Savage et al., 1985).
Results are expressed as pmol per gram of wet tissue.
Survival curves
Survival curves were constructed using GraphPad PRISM software 5.01. We
assigned values of 1 to events of premature recorded death and 0 to events
of death where the precise time of death was either not well defined or was
unknown owing to planned terminal studies or euthanasia owing to ill
health. Survival curves were compared using the Log-rank Mantel-Cox test.
Statistics
Data was analysed using GraphPad PRISM software, version 5.01. Two-
tailed, unpaired Student’s t-tests with Bonferroni correction and one-way
and two-way ANOVA (normal, not repeated measures) were used to
calculate P-values where appropriate. P-values ≤0.05 were considered
significant. Data are expressed as mean±s.e.m. or mean±s.d.
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